Morgan R G
Department of Pediatrics, University of Southern California, Los Angeles.
Cancer. 1989 Mar 15;63(6 Suppl):1008-12. doi: 10.1002/1097-0142(19890315)63:6+<1008::aid-cncr2820631303>3.0.co;2-z.
Exposure of tumor cells to reduced folates before or with the fluoropyrimidines, 5-fluorouracil or 5-fluoro-2'deoxyuridine, results in a substantial increase in the activity of these drugs. Available evidence suggests that the mechanism of this synergism is a kinetic stabilization of complex formed between thymidylate synthase and fluorodeoxyuridylate that also involves a mole of the cofactor for the thymidylate synthase reaction, 5,10-methylenetetrahydrofolate. This effect results in an extended time of depletion of thymidine nucleotides with a resultant increased level of cell death. The biochemical aspects of this interaction are discussed and related to the therapeutics of this combination.
在使用氟嘧啶(5-氟尿嘧啶或5-氟-2'-脱氧尿苷)之前或同时让肿瘤细胞接触还原型叶酸,会使这些药物的活性大幅增加。现有证据表明,这种协同作用的机制是胸苷酸合酶与氟脱氧尿苷酸之间形成的复合物的动力学稳定,这一过程还涉及一分子胸苷酸合酶反应的辅因子5,10-亚甲基四氢叶酸。这种效应导致胸苷核苷酸耗竭时间延长,从而使细胞死亡水平升高。本文讨论了这种相互作用的生化方面,并将其与这种联合疗法相关联。